Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obesity-Focused Zafgen Raises Zaftig Series B

This article was originally published in The Pink Sheet Daily

Executive Summary

Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.

You may also be interested in...



Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II

Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.

Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II

Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.

Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics

Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel